s S73 Results: From the day patients were discharged home after de novo LVAD surgery, the average cumulative cost of care increased from $87.9K to $161K and $314.9K at 1-, 2and 3years, respectively. Nearly half of these costs were related to recurrent hospitalizations. Of the 116 patients studied, 79 (68%) patients required more than one admission (range: 1-17). There was a linear association between the number of admissions and the costs of care (both IP and OP, p< 0.001). While the cumulative cost of uncomplicated LVAD (0-1 admissions) averaged $52.5K at 3-years, the costs increased 5-fold reaching $274.5K for those who required recurrent readmissions. These costs were equally distributed between OP ($176.5K) and IP care ($188.1K). Conclusion: We show that the costs of long-term MCS increase exponentially over time for those patients who require readmissions due to medical complications, reaching 5-fold the $50K cost of uncomplicated LVAD at 3-years. This trend should be taken into consideration when estimating costeffectiveness of long-term MCS especially in elderly patients with multiple comorbidities.